Published in Science on November 10, 1995
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med (2000) 16.09
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Cancer immunotherapy comes of age. Nature (2011) 12.35
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00
T cell activation. Annu Rev Immunol (2009) 7.40
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med (2000) 6.45
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest (2003) 6.42
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 4.97
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science (2011) 4.96
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med (1998) 3.56
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53
Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A (2008) 3.40
CTLA-4: a negative regulator of autoimmune disease. J Exp Med (1996) 3.25
CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev (2009) 3.09
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 2.95
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother (2005) 2.84
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med (2012) 2.58
Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57
Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci U S A (1996) 2.53
OX40 costimulation turns off Foxp3+ Tregs. Blood (2007) 2.52
CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med (1997) 2.51
Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest (1999) 2.48
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
Metabolism, cell surface organization, and disease. Cell (2009) 2.41
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol (2011) 2.36
Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci U S A (1996) 2.34
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med (2009) 2.23
Cell fate decision: T-helper 1 and 2 subsets in immune responses. Arthritis Res (2000) 2.21
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19
Mechanisms maintaining peripheral tolerance. Nat Immunol (2009) 2.14
Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. Proc Natl Acad Sci U S A (1997) 2.14
Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat Immunol (2011) 2.12
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. J Clin Invest (2016) 2.06
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
How do regulatory T cells work? Scand J Immunol (2009) 2.02
Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00
PD-1 as a potential target in cancer therapy. Cancer Med (2013) 1.98
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97
Defective granule exocytosis in Rab27a-deficient lymphocytes from Ashen mice. J Cell Biol (2001) 1.95
Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev (2008) 1.88
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med (2014) 1.81
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med (2011) 1.80
Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology (2006) 1.79
Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest (2001) 1.78
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med (2011) 1.77
Protein kinase C-η controls CTLA-4-mediated regulatory T cell function. Nat Immunol (2014) 1.76
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun (2008) 1.75
The B7 family of immune-regulatory ligands. Genome Biol (2005) 1.74
Protective immunity to nematode infection is induced by CTLA-4 blockade. J Exp Med (1997) 1.72
Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol (2004) 1.72
CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 1.71
Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med (2012) 1.71
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol (2009) 1.70
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci U S A (1999) 1.70
The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. J Exp Med (2005) 1.70
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 1.67
Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci U S A (1997) 1.67
Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr Rev (2008) 1.66
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother (2006) 1.66
CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion. PLoS Pathog (2013) 1.65
The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity (2014) 1.64
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med (1998) 1.62
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2014) 1.58
B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Exp Med (1999) 1.57
Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol (1996) 1.56
The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. J Autoimmun (2007) 1.55
B7 family checkpoint regulators in immune regulation and disease. Trends Immunol (2013) 1.53
Altered proliferative response by T lymphocytes of Ly-6A (Sca-1) null mice. J Exp Med (1997) 1.53
A genome-wide association study of myasthenia gravis. JAMA Neurol (2015) 1.52
The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am (2000) 1.52
The Yin and Yang of T cell costimulation. Science (1995) 15.19
Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (2001) 23.42
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Molecular characterization of mitochondrial apoptosis-inducing factor. Nature (1999) 14.41
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell (1993) 14.39
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell (1998) 13.98
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity (1995) 10.65
A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature (1984) 10.02
Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell (1993) 9.84
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science (1997) 9.73
BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell (2001) 9.33
The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell (2000) 8.95
Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell (1995) 8.75
Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell (1997) 8.61
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature (1996) 8.37
tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev (2000) 8.35
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science (2000) 7.85
Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science (1989) 7.78
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
Differential T cell costimulatory requirements in CD28-deficient mice. Science (1993) 6.93
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol (1998) 6.38
The B7 and CD28 receptor families. Immunol Today (1994) 6.38
Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res (2001) 6.15
Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity (1997) 6.15
Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature (1991) 5.98
Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell (1998) 5.92
Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science (2000) 5.84
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity (1995) 5.77
BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev (2001) 5.66
Profound block in thymocyte development in mice lacking p56lck. Nature (1992) 5.48
Regulation of PTEN transcription by p53. Mol Cell (2001) 5.44
Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell (1998) 5.32
FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science (1998) 5.29
Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science (1995) 5.27
The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell (1996) 5.10
Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol (2001) 5.10
Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature (2001) 5.07
Role of the CD28 receptor in T-cell activation. Immunol Today (1990) 4.89
T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol (1987) 4.76
Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency. Cell (1986) 4.68
T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity (2001) 4.62
Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature (1997) 4.55
Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Mol Cell (1999) 4.55
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53
Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev (2000) 4.51
Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell (1993) 4.46
Levels of c-myc oncogene mRNA are invariant throughout the cell cycle. Nature (1985) 4.35
Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol (1994) 4.34
Mouse T cell antigen receptor: structure and organization of constant and joining gene segments encoding the beta polypeptide. Cell (1984) 4.34
Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science (1997) 4.23
Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci U S A (1995) 4.22
T-cell co-stimulation through B7RP-1 and ICOS. Nature (1999) 4.20
Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature (1998) 4.18
In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol Cell (2000) 4.10
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature (2000) 4.08
CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell (1991) 4.05
ICOS is essential for effective T-helper-cell responses. Nature (2001) 4.01
Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev (1998) 3.92